Newly Diagnosed With Esophageal Cancer: First Steps

Esophageal cancer comes in two main forms, and they behave like separate diseases.

Adenocarcinoma accounts for at least half of cases in the United States. It usually starts in the lower esophagus, often from Barrett esophagus. Long-standing acid reflux is the main driver. NCI's PDQ summary notes it now leads in Western countries. That is true above all among White men.

Squamous cell carcinoma accounts for roughly 30%. It can arise anywhere along the esophagus. Its main risk factors are tobacco and alcohol.

The screening PDQ adds detail. For adenocarcinoma, three risk factors stand out. They are reflux disease, obesity, and long-term use of medicines that relax the lower esophageal sphincter. It reports an odds ratio of 16.2 for a body mass index above 30. For squamous cell carcinoma, the list is different. It covers tobacco, alcohol, poor nutrition, and human papillomavirus infection.

The American Cancer Society projects about 22,530 new cases and 16,290 deaths in the United States for 2026. NCI's SEER data put the median age at diagnosis at 69.

This is not a cancer where treatment starts before staging is finished. The gap between stage I and stage III is the difference between an endoscopic procedure and months of chemotherapy, radiation, and major surgery.

PDQ gives accuracy figures for each test, and they are not interchangeable:

• Endoscopic ultrasound, or EUS: 85% to 90% accurate for how deep the tumor invades.
• CT of chest and abdomen: 50% to 80% accurate.
• PET-CT: better than the others for finding distant spread.
• EUS-guided fine-needle aspiration: samples suspicious lymph nodes directly.

Each answers a different question. EUS measures depth. CT and PET look for spread. Skipping one leaves a hole in the stage.

The TNM system rates depth from T0 to T4b. Regional nodes run from N0 to N3. Distant spread is M0 or M1. Tumor location is written as a distance in centimeters from the front teeth. That is how endoscopists measure.

One point is worth raising with your team. PDQ notes one thing worth checking. Positive lymph nodes in the abdomen do not always mean surgery is impossible. If you have been told surgery is off the table because of abdominal nodes, ask whether that conclusion has been reviewed at a tumor board.

Stage 0 to I. PDQ describes endoscopic resection or surgical resection. Very early tumors can sometimes be removed through the endoscope, without an esophagectomy.

Stage II to III. Treatment is multimodal, combining surgery, chemotherapy, and radiation. PDQ names the CROSS regimen. It is carboplatin and paclitaxel given with radiation, then surgery to remove the esophagus. This is why treatment order matters: chemotherapy and radiation come first, then surgery.

Stage IV. PDQ describes definitive chemoradiation or palliative measures. Endoscopic procedures are used to relieve difficulty swallowing.

NCI's SEER measurements for people diagnosed between 2016 and 2022 show a 5-year relative survival of 22.2% overall, and 48.9% for those diagnosed while the cancer is still localized. That difference is the argument for completing the full staging workup before anyone commits to a plan.

Swallowing and weight are not side issues here. They are part of the disease.

The PDQ summary on nutrition in cancer care puts malnutrition at 30% to 85% of patients with cancer. It accounts for 10% to 20% of deaths in this group. It raises treatment toxicity and lowers quality of life.

That summary also states that nutrition intervention works better when it starts early. In esophageal cancer, early means before chemoradiation, not after you have stopped being able to eat solids.

Ask at the first visit:

• Can I see a registered dietitian before treatment starts?
• Will a feeding tube be needed, and if so, is it better placed before treatment than during it?
• Which textures should I switch to now?

The nutrition PDQ names dysphagia, which means trouble swallowing. Texture changes and positioning help manage it. It calls for small, frequent meals when people feel full early. It also flags mucositis, meaning a sore, inflamed lining of the mouth and throat. That is a real barrier to eating solid food.

Call 911 or go straight to an emergency department for any of these:

• Vomiting blood, or stools that are black and tarry. That is bleeding into the gut, and it needs treating within the hour, not tomorrow.
• Inability to swallow your own saliva, or food and liquid that will not go down at all.
• Coughing or choking every time you swallow, which suggests material entering the airway.
• A temperature of 100.4°F (38°C) or higher once chemotherapy has started. CDC calls that a medical emergency, and says to tell staff you are on chemotherapy.

Call the clinic the same day if you cannot keep liquids down for 24 hours, or if swallowing has narrowed further since the last visit.

A complete blockage is not something to wait out until the next scheduled appointment.

NIDDK describes Barrett esophagus as a change in the lining. The lining of the esophagus comes to resemble the lining of the intestine. About 5% of U.S. adults have it, compared with roughly 1% worldwide.

NIDDK lists the risk profile. It includes reflux disease, male sex, White race, and age 50 or older. Tobacco use and extra weight around the middle count too. So does a family history of Barrett esophagus or esophageal cancer.

Most people with Barrett esophagus never develop cancer. The screening PDQ puts the yearly risk of turning into cancer at roughly 0.5%. Published reports range from 0.2% to 1.9%. PDQ warns that publication bias may inflate those numbers.

Dysplasia is the intermediate step. NIDDK explains that it means abnormal cells in Barrett tissue, showing up before cancer does. It is graded low or high, based on how the cells look under the microscope.

Surveillance intervals in the PDQ summary follow that grading:

• No dysplasia: endoscopy every 2 to 3 years.
• Low-grade dysplasia: every 6 months at first, then yearly if stable.
• High-grade dysplasia: surgical removal, or repeated endoscopic evaluation.

PDQ is candid that these intervals rest on uncontrolled case series and expert opinion rather than randomized trials. It also notes that endoscopy carries rare but serious risks. Those are a tear in the wall, heart and lung events, and bleeding. The rate is 0 to 13 complications per 10,000 procedures.

Population-wide screening for esophageal cancer is not recommended. PDQ concludes it would not meaningfully lower deaths across the U.S. population.

• Is this adenocarcinoma or squamous cell carcinoma?
• Have I had EUS, CT, and PET-CT, and did any of them disagree?
• What is the clinical stage, and what is the tumor's distance from the incisors?
• Is the plan chemoradiation first, then surgery, or something else?
• Which hospital will do the esophagectomy, and how many do they perform each year?
• When will I see a dietitian, and is a feeding tube part of the plan?

• https://www.cancer.gov/types/esophageal/hp/esophageal-treatment-pdq
• https://www.cancer.gov/types/esophageal/hp/esophageal-screening-pdq
• https://www.cancer.gov/about-cancer/treatment/side-effects/appetite-loss/nutrition-hp-pdq
• https://www.niddk.nih.gov/health-information/digestive-diseases/barretts-esophagus/definition-facts
• https://www.cdc.gov/cancer-preventing-infections/patients/fever.html